Prof. Dr. med. Peter Fasching

Professur für Translationale Frauenheilkunde und Geburtshilfe

Update Breast Cancer 2022 Part 6 – Advanced-Stage Breast Cancer (2023) Lüftner D, Lux MP, Fehm TN, Welslau M, Müller V, Schütz F, Fasching P, et al. Journal article, Review article Update Breast Cancer 2022 Part 5 – Early Stage Breast Cancer (2023) Fehm TN, Welslau M, Müller V, Lüftner D, Schütz F, Fasching P, Janni W, et al. Journal article, Review article Breast Cancer and Genetic BRCA1/2 Testing in Routine Clinical Practice: Why, When and For Whom? (2023) Lux MP, Fasching P Journal article, Review article CCNE1 and survival of patients with tubo-ovarian high-grade serous carcinoma: An Ovarian Tumor Tissue Analysis consortium study (2023) Kang EY, Weir A, Meagher NS, Farrington K, Nelson GS, Ghatage P, Lee CH, et al. Journal article Systemic Therapy of Premenopausal Patients with Early Stage Hormone Receptor-Positive, HER2-Negative Breast Cancer - Controversies and Standards in Healthcare (2023) Müller V, Fasching P, Nabieva N, Fehm TN, Thill M, Schmidt M, Kühn T, et al. Journal article, Review article Expression of the Immunohistochemical Markers CK5, CD117, and EGFR in Molecular Subtypes of Breast Cancer Correlated with Prognosis (2023) Schulmeyer C, Fasching P, Häberle L, Meyer J, Schneider M, Wachter D, Rübner M, et al. Journal article Characterization of Hormone Receptor and HER2 Status in Breast Cancer Using Mass Spectrometry Imaging (2023) Gonçalves JPL, Bollwein C, Noske A, Jacob A, Jank P, Loibl S, Nekljudova V, et al. Journal article FANCM missense variants and breast cancer risk: a case-control association study of 75,156 European women (2023) Figlioli G, Billaud A, Ahearn TU, Antonenkova NN, Becher H, Beckmann M, Behrens S, et al. Journal article Lifetime ovulatory years and risk of epithelial ovarian cancer: a multinational pooled analysis (2023) Fu Z, Brooks MM, Irvin S, Jordan S, Aben KKH, Anton-Culver H, Bandera E, et al. Journal article Margetuximab Versus Trastuzumab in Patients With Previously Treated HER2-Positive Advanced Breast Cancer (SOPHIA): Final Overall Survival Results From a Randomized Phase 3 Trial (2023) Rugo HS, Im SA, Cardoso F, Cortes J, Curigliano G, Musolino A, Pegram MD, et al. Journal article